7 Tesla and Beyond

Abstract

Ultrahigh magnetic fields offer significantly higher signal-to-noise ratio, and several magnetic resonance applications additionally benefit from a higher contrast-to-noise ratio, with static magnetic field strengths of B 0 ≥ 7 T currently being referred to as ultrahigh fields (UHFs). The advantages of UHF can be used to resolve structures more precisely or to visualize physiological/pathophysiological effects that would be difficult or even impossible to detect at lower field strengths. However, with these advantages also come challenges, such as inhomogeneities applying standard radiofrequency excitation techniques, higher energy deposition in the human body, and enhanced B 0 field inhomogeneities. The advantages but also the challenges of UHF as well as promising advanced methodological developments and clinical applications that particularly benefit from UHF are discussed in this review article.

Scaling the mountains: what lies above 7 Tesla magnetic resonance?

“…Images from these instruments have revealed new aspects of anatomy, function and physio-metabolic characteristics of the neuro, neurovascular, cardiovascular, musculoskeletal, renal, hepatic and ocular systems, as well as other organs and tissues with unparalleled detail. UHF-MR has shown an amazing spectrum of potential clinical uses, with implications for neuroscience, neurology, radiology, neuroradiology, cardiology, internal medicine, oncology, nephrology, ophthalmology and many other clinical fields [1][2][3][4][5][6][7].…”

Test–retest stability of spontaneous brain activity and functional connectivity in the core resting‐state networks assessed with ultrahigh field 7‐Tesla resting‐state functional magnetic resonance imaging

“…More than 20 years since the first UHF-MRI scanners were approved for use in human (Robitaille et al, 1999;Yacoub et al, 2001), results from various areas of medicine demonstrate numerous unambiguous advantages of using this technology (Düzel et al, 2021;Platt et al, 2021;Vachha & Huang, 2021). Nevertheless, numerous technical challenges still need to be solved so that the applicability remains limited, especially in the field of clinical research (Düzel et al, 2021;Ladd et al, 2018).…”

The RPL/RPS Gene Signature of Melanoma CTCs Associates with Brain Metastasis

“…4) was performed biweekly to monitor MBM progression and to determine any ensuing MBM. MRI was carried out using the advanced 7-Tesla MRI scanner with high signal-to-noise ratio, translating into enhanced resolution and improved differentiation among brain tissue (50). No brain masses were visible by MRI by the third timepoint (25 days postinjection; Fig.…”